Solid Biosciences' SGT-003 Gene Therapy For Duchenne Muscular Dystrophy Granted Innovation Passport Under New Innovative Licensing And Access Pathway

Author: Benzinga Newsdesk | November 06, 2025 08:27am

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that SGT-003, the Company's investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP. The Innovation Passport is the entry point for the ILAP, which aims to accelerate time to market and facilitate patient access to new medicines in the UK. The Innovation Passport activates the MHRA and the ILAP partner agencies to develop a product-specific roadmap for regulatory and development milestones.

Posted In: SLDB